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Abstract
Background: It is well established that chronic tumor growth results in functional inactivation of T cells and NK cells. It is less
clear, however, whether lymphopoeisis is affected by tumor growth.
Principal Findings: In our efforts of analyzing the impact of tumor growth on NK cell development, we observed a major
reduction of NK cell numbers in mice bearing multiple lineages of tumor cells. The decrease in NK cell numbers was not due
to increased apoptosis or decreased proliferation in the NK compartment. In addition, transgenic expression of IL-15 also
failed to rescue the defective production of NK cells. Our systematic characterization of lymphopoeisis in tumor-bearing
mice indicated that the number of the common lymphoid progenitor was significantly reduced in tumor-bearing
mice. The number of B cells also decreased substantially in tumor bearing mice.
Conclusions and Significance: Our data reveal a novel mechanism for tumor evasion of host immunity and suggest a new
interpretation for the altered myeloid and lymphoid ratio in tumor bearing hosts.
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Introduction
Hematopoiesis is the process that generates leukocytes,
erythrocytes and megakaryocytes. It has been divided into two
branches[1], the lymphoid branch that generates B cells, T cells,
NK cells and dendritic cells, and the myeloid branch that produces
granulocytes, monocytes, dendritc cells, erythrocytes and mega-
karyocytes [2]. There appears to be two layers of regulation [3].
The first layer of control has been refered to as basal
hematopoiesis. It is responsible for maintaining normal blood cell
production and is regulated by cytokines produced within the
microenvironment of the bone marrow. The second regulatory
layer has been called amplified hematopoiesis. Amplified hema-
topoiesis is caused by physiological stress and appears to be
regulated by the endocrine system. Cytokines or metabolites
produced beyond the microenvironment of the bone marrow
signal the marrow by a combination of diffusion and plasma
transport. An example of amplified hematopoiesis is found in
tumor bearing mice. Many transplantable tumors secrete different
cytokines that act on bone marrow precursors among which are
GM-CSF, IL-3, M-CSF, IL-6 and VEGF [4]. In response to these
cytokines there is an expansion of myeloid cells that lead to
immunosuppression [5].
We have recently reported that natural killer (NK) cells are also
affected by soluble factors that are associated with tumor growth
[6]. In the aforementioned studies, NK cells were characterized as
being CD11b
lo and had impaired function in vivo. The immature
phenotype was associated with a deceased number of IL15-
Ra
+NK1.1
2CD3
2 cells in the bone marrow. Inhibition of NK cell
development has been blocked by the intentional disruption of
several genes including Flt-3L [7] and IL15 [8]. In Flt-3L and
interleukin (IL)-15 null mice, the NK cell number is drastically
reduced [7,8]. Depleted numbers of NK cells in Flt3L-deficient
mice is due to fewer common lymphoid progenitors [9]. In vitro
culture systems have demonstrated that Flt3L enhances the
expression of CD122 on human hematopoietic stem cells [10].
In a two-step culture system used to generate NK cells from
murine bone marrow, Flt3L is used in the initial step to produce
IL-15 responsive cells [11]. Although kit ligand (KL) is also used in
these cultures and stimulates CD122 expression, mice deficient in
KL have normal numbers of NK cells in the periphery [12].
Disruption of IL-15 [8] or components of the IL-15 recep-
tor[13,14] reduce NK cell numbers by preventing the induction of
Bcl-2 [15,16]. Thus IL-15 acts as a survival factor in NK cell
development.
In patients with CML, there is a progressive decrease in the
number of NK cells [17]. We previously demonstrated that NK
cell differentiation is inhibited in the bone marrow[6] and now
hypothesize that NK cell numbers may be reduced in association
with modifications of hematopoiesis. We found that as tumors
progress NK cell numbers decrease. The reduced number of NK
cells is not associated with an increase in apoptosis or a decrease in
PLoS ONE | www.plosone.org 1 September 2008 | Volume 3 | Issue 9 | e3180cellular proliferation, but a reduction in progenitor cell produc-
tion. The decrease in the common lymphoid progenitor may be
one early step of many which results in a dramatic decrease in
lymphocyte production as there is a substantial decrease also
found in B cell development.
Methods
Mice and Tumors
C57Bl/6 and Balb/c mice were purchased from Charles River
Laboratories under contract from the National Cancer Institute. B6
PLThy1,a./cy and C57Bl/6-LySU-Pep3B were purchased from
theJacksonLaboratory (Bar Harbor, ME). IL-15Tg mice have been
described [18]. All mice were housed in the University Laboratory
Animal Facility at The Ohio State University and University of
Michigan under specific pathogen-free conditions. All experiments
utilizing animals were approved by an institutional review board.
Thymoma EL4, melanoma B16F1 and colon cancer cell line
MC38 are syngeneic to C57Bl/6 mice. EL4 was grown in RPMI
1640 medium supplemented with 5% FBS, 100 U/ml penicillin,
100 mg/ml streptomycin and 4 mM L-glutamine. B16F1 and
MC38 were all grown in DMEM medium supplemented with 5%
FBS, 100 U/ml penicillin, 100 ug/ml streptomycin and 4 mM L-
glutamine.
Antibodies
The following fluorochrome-conjugated antibodies were pur-
chased from eBioscience (San Diego, CA): Fluorescein isothiocy-
anate (Fitc)-conjugated anti-Sca1 (clone D7); allophycocyanin
(APC)-conjugated anti-CD3e (clone 145-2C11); APC anti-CD117
(clone 2B8); phycoerythrin (PE) anti-CD127 (clone A7R34) and
PE anti-GR1 (clone RB6-8C5). The following fluorochrome-
conjugated antibodies were purchased from BD Pharmingen (San
Diego, CA): Peridinin chlorophyll protein Cy5.5 (PercpCy5.5)-
conjugated anti-NK1.1 (clone PK136); PercpCy5.5 anti-B220
(clone RA3-6B2); Fitc anti-CD11b (clone M1/70); PE-anti-
CD45.1 (clone A20); PE anti-CD122 (clone TM-b1); Fitc anti-
CD49b/Pan-NK cells (clone DX5), Fitc anti-BrdU (clone 3D4);
Fitc IgG1 isotype control (clone MOPC-21); PE-Annexin V and
streptavidin-PercpCy5.5. The Mouse Lineage Panel consisting of
biotinylated CD3, B220, CD11b, GR-1 and Ter119 were
purchased from BD Pharmingen.
Establishment of Subcutaneous Tumor
Syngeneic mice were subcutaneously injected with EL4
(5610
6 cells), B16F1 (1610
4 cells), or MC38 (5610
5 cells) viable
tumor cells. Mice were monitored every 2–3 days to evaluate
tumor growth and subcutaneous tumors were measured with a
caliper along perpendicular axes of the tumor. Mice were
sacrificed when tumors reached a size of 20 mm
2.
Cell Preparation and Flow Cytometry
Single cell suspensions were prepared from bone marrow and
spleen and were depleted of red blood cells. For flow cytometry,
cells were initially incubated with 2.4G2 supernatant to block
nonspecific antibody binding. Cells were then stained with four-
color combinations of indicated fluorochrome-conjugated mono-
clonal antibodies. Stained cells were fixed and analyzed with a
FACsCalibur (Becton Dickenson, San Jose, CA).
Apoptosis
Single cell suspensions were surface stained as described above,
in combination with fluorochrome-conjugated Annexin V and
samples were analyzed immediately with a FACsCalibur.
Bone Marrow Transplant
C57Bl/6 mice were sublethally irradiated and injected with
either EL4 tumors or PBS. 24 hours later bone marrow was
obtained from 10 C57BL/6-LySU-Pep3B mice that had been
treated 5-days earlier with 5FU. Approximately 1610
6 bone
marrow cells were intravenously injected into C57Bl/6j mice that
were previously injected with either PBS or EL4. After 3 weeks,
cells were isolated from the spleen and bone marrow of recipient
mice and analyzed by flow cytometry.
Statistics
Unless otherwise stated statistics were calculated by using an
unpaired Student’s T test (two tails). Significance was designated as
a p-value#0.05.
Results
Tumor-associacted reduction of NK cell number
Decreased numbers of NK cells have been observed in chronic
mylogenous leukemia[17]. In order to study the effects of tumor
cells on NK cell numbers, a suitable model was required. To
determine if the transplantable tumor cell line, EL4, would
diminish NK cell numbers a time course was performed to
evaluate tumor size with NK cell numbers. EL4 tumor growth was
monitored every 2–3 days, and every six days a subset of EL4
bearing mice were sacrificed to evaluate NK cell numbers. The
reduction of splenic NK cells is exemplified by the FACs profiles in
Fig 1A that shows a 3-fold reduction in NK cell percentage. The
absolute number of NK cells also decreased as the tumor increased
in size (Fig 1B). In multiple experiments comparing the cellularity
of splenocytes obtained from EL4 bearing mice and the control
mice, the EL4-bearing mice showed no reduction in splenocyte
cellularity. However, the number of NK cells in the spleen was
reduced (Fig 1C). Given evidence that NK cell development
occurs in the murine bone marrow [19,20] we evaluated the
number of NK cells in that organ. As in the spleen, the percentage
of NK cells was reduced in the bone marrow of tumor-bearing
mice Fig 1D. With the cellularity in the bone marrow being equal,
the reduced percentage of NK cells coincided with a reduction in
NK cell numbers (Fig 1E.) These data demonstrate that EL4
reduces NK cell numbers.
To determine if a reduction of NK cells occurs with other
murine tumors, C57Bl/6 mice were challenged with MC38 colon
cancer and B16F1 melanoma. Mice bearing MC38 tumors had a
strong reduction of NK cells in the bone marrow with a less
significant drop off of NK cells in the spleen (Table 1). Different
from EL4 and MC38 the B16F1 tumor demonstrated a greater
reduction in NK cell number in the spleen than in the bone
marrow (Table 1). These findings suggest that multiple tumors
lead to a reduction in NK cell numbers in both the bone marrow
and spleen.
NK cell Reduction is independent of apoptosis,
proliferation and IL15
Patients with head and neck cancer, breast cancer and chronic
myelogenous leukemia have demonstrated reduced numbers of
NK cells due to an increase in NK cell apoptosis[21,22]. To
determine if apoptosis causes a reduction in NK cells numbers in
EL4-bearing mice, Annexin V staining was performed on splenic
NK cells. As shown in Fig. 2A, a reduced percentage of NK cells
was observed in the spleen of tumor-bearing mice. The percentage
of NK cells undergoing apoptosis in these mice, however, was not
significantly different than that found in the control mice. Bone
marrow and liver cells were also stained for Annexin V, but again,
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Figure 1. EL4 tumor growth causes a decrease in splenic and bone marrow NK cells. Mice were injected subcutaneously with 5610
6 EL4
cells and compared to mice that received PBS. The number of NK cells was calculated by multiplying the percentage of NK cells by the cellularity of
the spleen or bone marrow. A. FACs profile of splenocytes stained with CD3 and NK1.1. NK cells were characterized as NK1.1
+CD3
2. The percentage
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Breed
Number of
Mice
Number of
Experiments Tumor Spleen p-value Bone Marrow p-value
C57Bl/6 28 7 Control 1.63610
661.9610
5 4.27610
568.0610
4
28 EL4 1.01610
661.3610
5 0.005* 2.68610
567.1610
4 0.002*
4 1 Control 1.42610
662.2610
5 1.01610
662.2610
5
4 B16F1 0.54610
661.6610
5 0.010 0.59610
661.2610
5 0.053
9 2 Control 1.34610
667.4610
5 2.70610
561.8610
4
9 MC38 0.74610
660.2610
5 0.32* 0.96610
561.8610
4 0.001*
*p-value was calculated using a paired t test.
doi:10.1371/journal.pone.0003180.t001
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Figure 2. Apoptosis and NK cell proliferation do not account for NK cell depletion. Mice were injected subcutaneously with PBS or 5610
6
EL4 cells. After 3 weeks, control and EL4-bearing mice were sacrificed and splenocytes were stained. A. The percentage of Annexin V
+NK1.1
+CD3
2
cells was used to determine the level of NK cell apoptosis. B. Three hours prior to euthanasia control and tumor-bearing mice were injected with
BrdU. Splenic NK cells were then stained for intracellular BrdU. The splenic NK cell population was gated on CD122
+CD3
2 cells. Data shown were
means and SEM, involving 5 mice per group.
doi:10.1371/journal.pone.0003180.g002
of NK cells is given as the mean6SEM of five animals. B. Kinetics of tumor growth and reduction of NK cells. Spleens from EL4 bearing mice were
obtained every six days and compared to control mice that were sacrificed on day 0. EL4 tumor growth was measured using calipers and the average
diameter was obtained from the width and length of the tumor. C. Splenic cellularity and NK cell number from control and EL4-bearing mice. Each
symbol represents the mean of a separate experiment. A paired T test was used to calculate the p-value. D. FACs profile of the bone marrow. NK cells
are characterized as NK1.1
+CD3
2. The percentage of NK cells is given as the mean6SEM of five animals. E. Bone marrow cellularity and NK cell
number obtained from control and EL4-bearing mice from several experiments. The number of NK cells was calculated by multiplying the percentage
of NK cells by the number of bone marrow cells. Each symbol represents the mean of a separate experiment. A paired T test was used to calculate the
p-value. Data in C–E were obtained when mice reached early removal criteria, i.e., the tumor reached 2 cm in diameters, usually at 4 weeks after
tumor challenge.
doi:10.1371/journal.pone.0003180.g001
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apoptosis (data not shown).
An alternative explanation for the reduction in NK cell
numbers seen in tumor-bearing mice is that NK cell proliferation
is reduced. To examine the proliferation of NK cells we pulsed
tumor-free and tumor-bearing mice with BrdU three hours prior
to euthanasia. Splenocytes were stained for the incorporation of
BrdU. As shown in Fig. 2B, the percentage of BrdU positive cells
was actually higher among NK cells in the spleen of tumor-bearing
mice. There no defect in proliferation can account for the decrease
in NK cell numbers.
Interleukin-15 knock out mice have reduced numbers of NK
cells[8]. To determine if IL15 deficiency perpetuated the loss of
NK cells seen in tumor-bearing mice, mice that over express IL15
were challenged with EL4 to determine if IL15 prevents a loss in
NK cell number. PBS and EL4 were injected into IL-15Tg mice
or littermate controls. As expected IL-15Tg mice displayed an
increased percentage of NK cells compared to wild type control
mice (Fig 3A). However, like wild type control mice, the presence
of EL4 in IL-15Tg mice resulted in a reduction in the percentage
of bone marrow NK cells (Fig 3A). The cellularity in the bone
marrow of EL4-bearing, IL-15Tg mice was the same as IL-15Tg
control mice and wild type mice (Fig 3B). Thus, IL-15Tg and wild
type control mice that have EL4 tumors have decreased NK cell
numbers (Fig 4B), and this decrease in NK cell numbers is
independent of IL15.
Tumor-associated decrease in common lymphoid
progenitors
In vitro studies have demonstrated that IL15 does not induce the
generation of NK cells directly from hematopoietic stem cells [23].
Instead a cocktail of cytokines that include Flt3L, KitL, IL7 and IL6
are required to induce IL-15 responsiveness, after which, the
addition of IL-15 will result in the generation of NK cells [23]. The
acquisition of CD122 is thought to commit cells to the NK cell
lineage and IL-15 responsiveness [24]. To determine if there is a
defect in NK cell precursors (NKP) we injected mice with EL4 and
PBS. NK cell progenitors were initially characterized as
CD122
+NK1.1
2CD3
2. FACs analysis of the bone marrow showed
a reduction in the NK1.1
+CD3
2 population, which demonstrates a
decrease in NK cells (Fig 4A). Furthermore, the
CD122
+NK1.1
2CD3
2 population also decreased suggesting a
decrease in NKP (Fig 4A). Upon calculating the absolute number of
NKP, there was an approximate 2-fold reduction in tumor-bearing
mice (Fig 4B). These data suggest a defect in the acquisition of NKP
as a cause for reduced NK cells in EL4 bearing mice.
Given the plausibility that NK cell progenitors are decreased in
tumor bearing mice, there may be further hematopoietic defects.
To evaluate this hypothesis, tumor-bearing mice were evaluated
with a panel of antibodies to evaluate the number of NK cells, NK
cell progenitors, common lymphoid progenitors (CLP), hemato-
poietic stem cells (HSCs) and B cells. HSCs belong to the
Lin
2CD127
2cKit
+Sca1
+ population[25]. To evaluate the HSC
pool, gated Lin
2CD127
2 cells were evaluated for cKit
+Sca1
+
(Fig. 5A). The percentage of HSCs from both EL4-bearing mice
and control mice were approximately equal, suggesting that the
HSC pool was not affected by tumor growth. The CLP,
characterized as Lin
2CD127
+cKit
intSca1
int[26], however, was
reduced by about 50% (Fig 5A). The major point of reduction
was associated with a decrease in CD127 expression as the
corresponding cells that expressed intermediate levels of cKit and
Sca1 were approximately equal (Fig 5A). To more stringently
define NKP, bone marrow cells were stained for the NKP as
marked by CD122
+NK1.1
2DX5
2CD3
2 [24]. Bone marrow cells
were gated on the CD122
+CD3
2 cell population, which were
greatly reduced in EL4-bearing animals (Data not shown). The
gated population was then evaluated for NK1.1 and DX5
expression. Interestingly, there was a slight increase in the
percentage of CD122
+NK1.1
2DX5
2CD3
2 (Fig. 5B), although
the absolute number was decreased. Since NK cells are a third
subset of lymphocytes, we tested whether B cell number is also
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Figure 3. IL15 does not prevent loss of NK cell number. IL15Tg
and littermate controls were injected with PBS or EL4. After 3 weeks,
bone marrow was evaluated for NK cell number. A. FACs profile of
NK1.1
+CD3
2 cells obtained from WT or IL15Tg mice with or without
tumor. B. Bone marrow cellularity and absolute number of NK cells. The
absolute number of NK cells was calculated by multiplying the
percentage of NK1.1
+CD3
2 cells by the number of bone marrow cells.
Data shown were means and SEM, involving 4 mice per group.
doi:10.1371/journal.pone.0003180.g003
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Interestingly, we also observed a significant decrease in the
percentage of B cells as characterized by the B cell marker B220
(Fig 5C). The absolute number of cells correlated well with the
percent reduction is observed in Fig 5A–C. In several experiments
HSCs were relatively equal, while there were decreases observed
in the CLPs, NKPs and B cells (Fig 5D). These data suggest that
lymphopoiesis is altered in EL4-bearing animals.
To confirm that there is an alteration in lymphopoiesis in EL4-
bearing animals a bone marrow transplant was performed. Mice
were sub-lethally irradiated prior to tumor injection. One day
later, 5FU treated bone marrow cells, from CD45.1 congenic mice
were injected intravenously into control and tumor bearing mice
and cellular differentiation was evaluated approximately three
weeks later. In general, it was found that CD45.1 cells were
expanded to a greater extent in tumor bearing mice (data not
shown). However, the donor NK cell population was dramatically
decreased (Fig 6B). Absolute numbers of donor NK cells (Fig. 6C)
and B cells (Fig 6D) were also decreased.
Since NK and B cells are both derived from CLP, we tested the
hypothesis that a reduction in this subset is an underlying cause for
both defects. As shown in Fig. 6E and F, the donor CLP, as
defined by CD45.1
+Lin
2CD127
+cKit
int markers, was reduced in
both % and absolute numbers. Taken together, the congenic
transfer of CD45.1
+ cells into control and tumor bearing mice
demonstrate that tumor growth leads to a block of differentiation
into the lymphoid lineage.
Discussion
In a previous study we demonstrated that EL4 tumors secrete a
soluble factor that modifies IL15Ra expression, which is associated
with defective NK cell differentiation[6]. One aspect of NK cell
development that was not thoroughly evaluated in that manuscript
was the decrease in NK cells found in EL4-bearing mice. As we
found that IL15Ra was decreased in the bone marrow, we
hypothesized that modifications of hematopoietic processes may
result in a decrease in NK cell number.
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Figure 4. NK cell progenitors are reduced in EL4 tumor-bearing mice. B6 mice were injected with PBS or EL4 and sacrificed after 21 days. NK
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2. A. FACs profile of NK cell progenitors. B. Absolute number of progenitors was calculated
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doi:10.1371/journal.pone.0003180.g004
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hematopoiesis is regulated in the bone marrow by cytokines that
act in a paracrine manner to maintain the production of all the
different hematopoietic lineages[3]. It is only upon a stress in
which cytokines released into circulation act in an endocrine
manner to modify hematopoietic production[3]. Tumors are a
prime example of a stress that results in the production of
cytokines. Many transplantable tumors have been found to secrete
cytokines that modify hematopoeisis[4]. Some of these cytokines
include TGF-b, VEGF-A and GM-CSF amongst others[27,28].
The ability for tumor growth depends on their ability to obtain
nutrients from the circulation. To meet this demand many tumors
secrete VEGF-A, which induces vasculariztion[29]. VEGF-A has
been shown to act on bone marrow cells, which leads to an
increase in GR-1/CD11b immature myeloid cells[5].
In EL4-bearing mice, GR-1/CD11b myeloid cells were
increased in both the bone marrow and spleen (Data not shown).
The development of GR1/CD11b myeloid cells is associated with
a large tumor burden and a state of immune suppression[30].
Immune suppression by GR1/CD11b is associated with a
decrease in T cell function[30]. Interestingly, ablation of NK cells
in BW-Sp3 tumor-bearing mice results in favorable growth
conditions for GR-1/CD11b myeloid cells[31]. In Figure 1B we
observed an inverse relationship between NK cell number and
tumor growth.
There have been several reports that have demonstrated a
decrease in NK cell number in patients with tumors[17,21,22].
Most of these reports have shown that there was an increase in NK
cell apoptosis. In evaluating NK cell apoptosis we observed no
significant difference in cellular death. Furthermore, there was an
increase in NK cell proliferation. Lymphopenic animals undergo
homeostatic proliferation to restore T cell numbers and a similar
phenomenon may be occurring within the NK cell compartment
of tumor-bearing mice in an attempt to restore the number of NK
cells [32]. With equal levels of cellular death and increased
proliferation of NK cells in EL4 bearing-mice compared to control
mice there should be a net increase in the NK cell number.
However, we demonstrated that the pool of NK cells continually
drops with tumor enlargement.
Two independent studies have demonstrated that transgenic
expression of Bcl2 maintains NK cell number in IL15
2/2 mice
and that IL15 is important for NK cell survival[15,16]. Early
hematopoietic progenitor cells are not responsive to IL15 and
upon upregulation of CD122 hematopoietic precursors become
commited to the NK cell lineage[23,24]. However, IL-15
transgene failed to rescue decreased levels of NK cells after tumor
challenge. These data suggested that an earlier stage of NK cell
development may be responsible for the decrease in NK cell
numbers. The first candidate to consider was the NKP
characterized as being CD122
+NK1.1
2DX5
2CD3
2 [24]. We
observed two main differences in NKPs. First, the overall number
of NKPs was reduced in tumor-bearing mice compared to
wildtype animals. The reduction was similar to that seen in total
NK cell numbers. Therefore the decrease in NK cell number is
likely due to reduction in the number of cells entering into the NK
cell lineage. Second, when NKPs were gated on CD122
+CD3
2
cells there was an approximate two-fold increase in the percentage
of NK1.1
2DX5
2 cells in tumor-bearing mice compared to control
mice. This suggests that NKPs may also be blocked in their
progression to become NK cells. To exemplify this point it was
observed in congenic bone marrow transplants that there was a 2
to 3 fold accumulation of recipient and donor NKPs, in tumor-
bearing mice compared to control mice.
Given that NK cells are a third subset of lymphocytes, it is
plausible that earlier progenitor cells are also impaired in tumor-
bearing animals. Our data revealed that a reduction in NK cells in
tumor-bearing animals also correlates with a decline in the
number of CLP. As with NK cells and NKPs, the CLP is reduced
by approximately 50% in tumor-bearing animals while the HSC
population is constant. Furthermore, there was a substantial
decrease in B cell development. Defects in B cell development
have previously been reported in transgenic mice that overexpress
arginase[33]. Increases in arginase concentration have been
associated with the production GR-1/CD11b myeloid cells[4].
The mechanism by which NK cells are affected by tumors
remains elusive. We have evaluated antibodies to neutralize TGF-
b in the EL4 model and blocking antibodies against VEGFR1 and
VEGFR2 in the MC38 model (Data not shown). Neutralization of
TGF-b, TNFa and blocking antibodies against VEGFR1 and
VEGFR2 had no effect on NK cell number (data not shown). We
also evaluated EL4 transcripts for GM-CSF, G-CSF, SCF and IL6
amongst others in an RNAse protection assay to determine if any
cytokines that potentially inhibit NK cell development could be
detected (data not shown). There was no indication of cytokines
that modify hematopoietic development in EL4.
Regardless of the mechanism, our study appears to be the first
to show tumor growth leads to reduced lymphopoiesis, which in
turn results in a decrease in NK and B cell numbers. Linking
tumor growth to abnormal hematopoiesis in animal model may
lead to new approaches aiming at boosting host immunity to
cancer.
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